



2009 BIO International Convention  
Neglected Diseases Initiative

May 21, 2009


David Perry, Chief Executive Officer



A Biopharmaceutical Company  
Developing Multiple Drug Candidates  
Using Novel and Proprietary  
Boron Chemistry



# Large Pipeline of Novel Proprietary Candidates



# Neglected Disease Programs

<ul style="list-style-type: none"> <li>● African Sleeping Sickness</li> <li>● Visceral Leishmaniasis</li> <li>● Chagas disease</li> </ul>	<ul style="list-style-type: none"> <li>● Tuberculosis</li> </ul>	<ul style="list-style-type: none"> <li>● Malaria</li> <li>● Filarial Worms</li> </ul>
<p style="text-align: center;"><u>Secondary Role</u></p> <p>Leadership role in applying boron chemistry</p>	<p style="text-align: center;"><u>Primary Role</u></p> <p>Drug discovery leadership with biology collaborator</p>	<p style="text-align: center;"><u>Primary Role</u></p> <p>Drug discovery leadership with biology collaborator</p>

## Possible ancillary benefits to Anacor

- Expands diversity and number of boron-containing compounds
- Increases our scientific knowledge base of our platform technology
- Employees like it
- Some market-based incentives
  - FDA Priority Review Voucher
  - Sales (TB, malaria, veterinary use)

## DNDi Deal Structure

- License

- *Non-exclusive, royalty-free license to all IP*

- Territory: Developing countries
    - Field: HAT, leishmaniasis, Chagas disease
    - Public Sector Markets (Governments, Nonprofits)
    - Ability to sublicense

- Collaboration IP owned by Anacor

- Anacor responsible for IP
    - Anacor retains all rights in the developed world, and for any applications in treating other diseases